# Prostate cancer

Source: https://nuclide.cc/indications/prostate/  
Nuclide record `prostate` (Indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype.

## Summary

Prostate cancer is the most common cancer in men in most high-income countries and a spectrum: most PSA-detected disease is indolent and safely watched (ProtecT: ~3% prostate-cancer mortality at 15 years whatever the strategy), while de novo metastatic disease, treated with hormonal doublets and triplets and since 2026 with radioligand therapy added, still has a median survival of about five years, which makes it the second most common cause of cancer death in men. Diagnosis now runs PSA → multiparametric MRI (PRECISION) → targeted biopsy → Grade Group, with germline and somatic HRR testing for advanced disease and PSMA PET for staging (proPSMA) and recurrence. Digital-pathology AI (ArteraAI Prostate, 2025) and gene-expression classifiers (Decipher) refine who needs treatment and who benefits from adding hormone therapy.

Treatment is built on androgen deprivation, the first targeted cancer therapy (Huggins, 1941). Metastatic hormone-sensitive disease is treated with doublets (ADT + abiraterone, enzalutamide, apalutamide or darolutamide) or triplets adding docetaxel (ARASENS, PEACE-1), and since 31 July 2026 with 177Lu-PSMA-617 added to ADT + ARPI (PSMAddition, rPFS HR 0.72). PTEN-deficient disease gained capivasertib + abiraterone in 2026. In castration-resistant disease the sequence includes ARPI switch, PARP inhibitors for HRR-mutant tumours (PROfound, PROpel, TALAPRO-2 with OS benefit), docetaxel and cabazitaxel, radium-223 for bone-only disease, and 177Lu-PSMA-617 before or after chemotherapy (VISION, PSMAfore). Enzalutamide is approved even for high-risk PSA-only recurrence (EMBARK).

Prostate cancer is the proving ground for theranostics: PSMA PET selects and PSMA radioligands treat. Competing 177Lu-PSMA-I&T products (SPLASH, ECLIPSE) have improved progression but not yet survival; alpha-emitting 225Ac-PSMA agents are in phase 3 (AlphaBreak, AcTION) and produce responses after lutetium failure. T-cell engagers against STEAP1 (xaluritamig, XALute) and KLK2 (pasritamig) are the first immunotherapies with real activity in a disease that ignores checkpoint inhibitors; EZH2 inhibition (mevrometostat, MEVPRO) aims to re-sensitise to hormonal therapy. The unsolved problems are neuroendocrine transformation, AR-V7-driven resistance (the N-terminal-domain inhibitor masofaniten failed), Ac-225 supply, and the over- versus under-diagnosis tension in screening.

## Fields

- Kind: Indication
- Last checked: 2026-09-06
- Tags: gu; spike
- Group: genitourinary
- Burden: ~1.5 million new cases per year worldwide; lifetime risk ~1 in 8 men in high-income countries; median age at diagnosis 67; most PSA-detected disease is indolent and safely watched. ~400,000 deaths per year worldwide, mostly from disease that was already metastatic at diagnosis.
- Subtypes: Localised: low / favourable-intermediate / unfavourable-intermediate / high risk (NCCN); Non-metastatic castration-resistant (nmCRPC); Metastatic hormone-sensitive (mHSPC; FDA 2026 term 'androgen pathway modulation-naive or -sensitive'), de novo vs recurrent, high vs low volume (CHAARTED); Metastatic castration-resistant (mCRPC); HRR-mutant (~20-25% of mCRPC; BRCA2 most actionable); PTEN-deficient (~25%); PSMA-low / heterogeneous (~10%); Treatment-emergent neuroendocrine prostate cancer (~15-20% of late mCRPC); Ductal and intraductal / cribriform variants (aggressive)
- Biomarkers: PSA; Gleason / Grade Group; PSMA PET; HRR genes (BRCA2, ATM, etc.); PTEN; MSI; AR-V7 (research); Decipher / ArteraAI; PSA, PSA density, PSA doubling time; Grade Group (Gleason) and cribriform/intraductal pattern; mpMRI PI-RADS score; PSMA PET (SUVmax, total tumour volume) for staging and radioligand eligibility; Germline and somatic HRR genes (BRCA2, BRCA1, ATM, PALB2, CDK12); PTEN loss (IHC or NGS) for capivasertib; MSI/dMMR (~3%, pembrolizumab); Decipher genomic classifier; ArteraAI digital pathology; AR-V7 (CTC) in research/limited use; Testosterone level (castration confirmation); Neuroendocrine markers (chromogranin, synaptophysin, RB1/TP53 loss) on progression

## Standard of care

- Localised: Active surveillance, prostatectomy, or radiation ± ADT (duration guided by risk/ArteraAI).
- Metastatic hormone-sensitive: ADT + ARPI ± docetaxel; PSMA PET staging; capivasertib if PTEN-deficient. ([PSMA PET](https://nuclide.cc/technologies/psma-pet/))
- Castration-resistant: ARPI switch, PARP inhibitor combinations (HRR+), 177Lu-PSMA-617, docetaxel/cabazitaxel, radium-223. ([Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/), [Olaparib](https://nuclide.cc/drugs/olaparib/), [VISION](https://nuclide.cc/trials/vision/), [PSMAfore](https://nuclide.cc/trials/psmafore/))
- Screening: Shared-decision PSA testing from 50 (45 if Black or family history/BRCA), risk-adapted intervals; MRI before biopsy; avoid biopsy if MRI negative and PSA density low.
- Localised, low / favourable-intermediate risk: Active surveillance (PSA, MRI, repeat biopsy) for Grade Group 1 and many favourable GG2; genomic classifier or ArteraAI to refine.
- Localised, unfavourable-intermediate / high risk: Radical prostatectomy (robotic) or radiotherapy (hypofractionated IMRT, SBRT, or brachytherapy boost) with 4-6 months (intermediate) to 18-36 months (high risk) of ADT; abiraterone added for very high risk (STAMPEDE); ArteraAI predicts ADT benefit. ([STAMPEDE](https://nuclide.cc/trials/stampede/))
- Biochemical recurrence: PSMA PET to localise; salvage radiotherapy ± ADT after prostatectomy; metastasis-directed SBRT for oligorecurrence (investigational for survival); enzalutamide ± ADT for high-risk BCR (EMBARK). ([PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Biochemical recurrence (BCR)](https://nuclide.cc/terms/biochemical-recurrence/), [EMBARK](https://nuclide.cc/trials/embark/), [Enzalutamide](https://nuclide.cc/drugs/enzalutamide/), [PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer](https://nuclide.cc/ideas/idea-psma-pet-guided-mdt/))
- Metastatic hormone-sensitive (mAPMN/S): ADT (GnRH agonist/antagonist, e.g., relugolix) + ARPI (abiraterone, enzalutamide, apalutamide, or darolutamide); add docetaxel for high-volume de novo disease (ARASENS, PEACE-1); add 177Lu-PSMA-617 if PSMA-positive (PSMAddition, approved 31 Jul 2026); capivasertib + abiraterone if PTEN-deficient (2026); prostate RT for low-volume disease. ([Abiraterone acetate](https://nuclide.cc/drugs/abiraterone/), [Enzalutamide](https://nuclide.cc/drugs/enzalutamide/), [Docetaxel](https://nuclide.cc/drugs/docetaxel/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/), [PSMAddition](https://nuclide.cc/trials/psmaddition/))
- Non-metastatic CRPC: Apalutamide, enzalutamide, or darolutamide (SPARTAN, PROSPER, ARAMIS); PSMA PET usually reclassifies as metastatic. ([Enzalutamide](https://nuclide.cc/drugs/enzalutamide/), [PSMA PET](https://nuclide.cc/technologies/psma-pet/))
- Metastatic CRPC, first line: ARPI (if not used earlier); PARP inhibitor + ARPI for BRCA/HRR-mutant (olaparib-abiraterone, talazoparib-enzalutamide, niraparib-abiraterone); docetaxel; 177Lu-PSMA-617 after one ARPI before chemotherapy (PSMAfore); pembrolizumab if MSI-high. ([Olaparib](https://nuclide.cc/drugs/olaparib/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/), [PSMAfore](https://nuclide.cc/trials/psmafore/), [Docetaxel](https://nuclide.cc/drugs/docetaxel/), [Pembrolizumab](https://nuclide.cc/drugs/pembrolizumab/))
- Metastatic CRPC, later lines: 177Lu-PSMA-617 post-taxane (VISION); cabazitaxel (CARD); radium-223 for bone-only symptomatic disease (with bone protection); 225Ac-PSMA, xaluritamig, pasritamig, mevrometostat in trials; platinum-etoposide for neuroendocrine transformation; tarlatamab/I-DXd trials for DLL3/B7-H3. ([Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/), [VISION](https://nuclide.cc/trials/vision/), [Cabazitaxel](https://nuclide.cc/drugs/cabazitaxel/), [Radium-223 dichloride](https://nuclide.cc/drugs/radium-223/), [ALSYMPCA](https://nuclide.cc/trials/alsympca/), [Actinium-225 PSMA agents](https://nuclide.cc/drugs/ac225-psma/), [AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)](https://nuclide.cc/trials/alphabreak/))

## State of the art

- Theranostic pairing of PSMA PET and Pluvicto.
- Genotype-directed doublets.
- AI pathology guiding ADT duration.
- Radioligand therapy across the metastatic continuum: 177Lu-PSMA-617 approved post-taxane (2022), pre-taxane (2025), and at first metastatic diagnosis with ARPI (31 July 2026).
- Triplet therapy (ADT + ARPI + docetaxel) for high-volume de novo disease, with OS HR ~0.7 (ARASENS, PEACE-1).
- Genotype-directed doublets: PARP inhibitor + ARPI for HRR-mutant (OS benefit in TALAPRO-2) and capivasertib + abiraterone for PTEN-deficient disease (2026).
- Diagnostic pathway rebuilt around MRI-first biopsy and PSMA PET staging; active surveillance is default for low-risk disease.
- AI pathology (ArteraAI Prostate) is FDA-authorised to predict who benefits from adding hormone therapy to radiation.
- First immunotherapies with real activity: STEAP1 and KLK2 T-cell engagers in phase 3, after checkpoint inhibitors failed in unselected disease.

## Open problems

- Overdiagnosis vs. underdiagnosis in screening.
- Neuroendocrine transformation.
- Ac-225 supply.
- Screening trade-off: PSA reduces mortality by ~20% but overdiagnoses; MRI-first and risk-adapted intervals are only partly adopted.
- Neuroendocrine / lineage-plastic transformation in ~15-20% of late mCRPC has no targeted therapy; DLL3 and B7-H3 agents are being borrowed from SCLC.
- AR-V7 and N-terminal-domain resistance: masofaniten failed; AR degraders remain preclinical/early.
- Radioligand sequencing and resistance: 10% PSMA-negative disease, heterogeneity, and no proven therapy after 177Lu failure outside trials; Ac-225 supply is the constraint.
- Overall survival has been hard to show for PSMA radioligands beyond VISION (SPLASH, PSMAfore, TheraP confounded by crossover).
- Immunotherapy: checkpoint inhibitors fail in unselected disease; engagers bring cytokine release and need outpatient models.
- Equity: Black men have ~70% higher incidence and double the mortality yet are under-enrolled in trials; earlier, risk-adapted screening is the lever.
- Bone health, cardiovascular risk, and cognitive effects of long-term ADT in men living a decade or more.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer

## Connected records

- roadmaps: [PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha](https://nuclide.cc/roadmaps/psma-theranostics-roadmap/), [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://nuclide.cc/roadmaps/radiopharma-roadmap/)
- pairings: [Beta radioligand → alpha radioligand](https://nuclide.cc/pairings/beta-then-alpha/), [PSMA PET → PSMA radioligand therapy](https://nuclide.cc/pairings/psma-pet-to-rlt/)
- collections: [Prostate Cancer Foundation (PCF)](https://nuclide.cc/collections/prostate-cancer-foundation/), [UroToday](https://nuclide.cc/collections/src-urotoday/)
- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Carbon-11](https://nuclide.cc/isotopes/c-11/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/), [Radium-223](https://nuclide.cc/isotopes/ra-223/), [Samarium-153](https://nuclide.cc/isotopes/sm-153/), [Strontium-89](https://nuclide.cc/isotopes/sr-89/)
- technologies: [Actinium-225 supply: thorium stocks, accelerators and radium targets](https://nuclide.cc/technologies/actinium-225-supply/), [Astatine-211 alpha therapy](https://nuclide.cc/technologies/astatine-211-alpha-therapy/), [Gamma probes, handheld gamma cameras and dose calibrators](https://nuclide.cc/technologies/gamma-probes-dose-calibrators/), [Low-dose-rate seed brachytherapy](https://nuclide.cc/technologies/ldr-seed-brachytherapy/), [Lutetium-177 radioligand therapy](https://nuclide.cc/technologies/lu177-radioligand-therapy/), [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)](https://nuclide.cc/technologies/quantitative-imaging-biomarkers/), [Radioligand plus DNA-repair inhibitor combinations](https://nuclide.cc/technologies/radionuclide-parp-combination/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [Radiopharmaceutical GMP and releasing a drug that decays](https://nuclide.cc/technologies/radiopharmaceutical-gmp-release/), [Research reactors for medical isotopes (Mo-99, Lu-177, I-131)](https://nuclide.cc/technologies/research-reactor-isotope-production/), [SPECT/CT](https://nuclide.cc/technologies/spect-ct/), [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/)
- targets: [B7-H3](https://nuclide.cc/targets/b7h3/), [DLL3](https://nuclide.cc/targets/dll3/), [GRPR (gastrin-releasing peptide receptor)](https://nuclide.cc/targets/grpr/), [KLK2 (kallikrein-2)](https://nuclide.cc/targets/klk2/), [PARP](https://nuclide.cc/targets/parp/), [PSMA](https://nuclide.cc/targets/psma/), [STEAP1](https://nuclide.cc/targets/steap1/), [uPAR (urokinase plasminogen activator receptor)](https://nuclide.cc/targets/upar/)
- drugs: [177Lu-PSMA-I&T](https://nuclide.cc/drugs/lu177-psma-it/), [AAA817](https://nuclide.cc/drugs/aaa817/), [Abiraterone acetate](https://nuclide.cc/drugs/abiraterone/), [Actinium-225 PSMA agents](https://nuclide.cc/drugs/ac225-psma/), [Cabazitaxel](https://nuclide.cc/drugs/cabazitaxel/), [Choline C-11](https://nuclide.cc/drugs/choline-c11/), [Docetaxel](https://nuclide.cc/drugs/docetaxel/), [Enzalutamide](https://nuclide.cc/drugs/enzalutamide/), [Florastamin F-18](https://nuclide.cc/drugs/florastamin-f18/), [Flotufolastat F-18](https://nuclide.cc/drugs/flotufolastat/), [Fluciclovine F-18](https://nuclide.cc/drugs/fluciclovine-f18/), [FPI-2265](https://nuclide.cc/drugs/fpi-2265/), [Gallium-68 gozetotide (PSMA-11)](https://nuclide.cc/drugs/ga68-psma-11/), [HRS-4357](https://nuclide.cc/drugs/hrs-4357/), [Illuccix (kit for Ga-68 gozetotide)](https://nuclide.cc/drugs/illuccix/), [Iodine-125 brachytherapy seeds](https://nuclide.cc/drugs/i-125-seeds/), [JNJ-87189401](https://nuclide.cc/drugs/jnj-87189401/), [Locametz (kit for Ga-68 gozetotide)](https://nuclide.cc/drugs/locametz/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/), [Olaparib](https://nuclide.cc/drugs/olaparib/), [Pembrolizumab](https://nuclide.cc/drugs/pembrolizumab/), [Piflufolastat F-18 / Pylarify TruVu](https://nuclide.cc/drugs/pylarify/), [PSMA-1007 F-18](https://nuclide.cc/drugs/psma-1007-f18/), [Radium-223 dichloride](https://nuclide.cc/drugs/radium-223/), [Samarium-153 lexidronam](https://nuclide.cc/drugs/samarium-153-lexidronam/), [Sodium fluoride F-18](https://nuclide.cc/drugs/f-18-naf/), [Technetium Tc-99m medronate (MDP)](https://nuclide.cc/drugs/tc-99m-mdp/), [Technetium Tc-99m PSMA agents (PSMA-I&S)](https://nuclide.cc/drugs/tc-99m-psma-imaging/)
- companies: [ABX advanced biochemical compounds](https://nuclide.cc/companies/abx-advanced-biochemical-compounds/), [Actinium Pharmaceuticals](https://nuclide.cc/companies/actinium-pharmaceuticals/), [Advanced Accelerator Applications (Novartis)](https://nuclide.cc/companies/advanced-accelerator-applications/), [Aktis Oncology](https://nuclide.cc/companies/aktis-oncology/), [Alpha Tau Medical](https://nuclide.cc/companies/alpha-tau-medical/), [ARTBIO](https://nuclide.cc/companies/artbio/), [AstraZeneca](https://nuclide.cc/companies/astrazeneca/), [Bayer](https://nuclide.cc/companies/bayer/), [Blue Earth Diagnostics (Bracco)](https://nuclide.cc/companies/blue-earth-diagnostics/), [Bracco Imaging](https://nuclide.cc/companies/bracco/), [Clarity Pharmaceuticals](https://nuclide.cc/companies/clarity-pharmaceuticals/), [Convergent Therapeutics](https://nuclide.cc/companies/convergent-therapeutics/), [Curium](https://nuclide.cc/companies/curium/), [FutureChem](https://nuclide.cc/companies/futurechem/), [Johnson & Johnson](https://nuclide.cc/companies/johnson-johnson/), [Lantheus](https://nuclide.cc/companies/lantheus/), [Novartis](https://nuclide.cc/companies/novartis/), [Pfizer (incl. Seagen)](https://nuclide.cc/companies/pfizer/), [POINT Biopharma](https://nuclide.cc/companies/point-biopharma/), [Radiopharm Theranostics](https://nuclide.cc/companies/radiopharm-theranostics/), [Telix Pharmaceuticals](https://nuclide.cc/companies/telix/)
- institutions: [All India Institute of Medical Sciences, New Delhi](https://nuclide.cc/institutions/aiims-delhi/), [ANZUP Cancer Trials Group](https://nuclide.cc/institutions/anzup/), [Chinese PLA General Hospital](https://nuclide.cc/institutions/pla-general-hospital/), [Erasmus MC Cancer Institute](https://nuclide.cc/institutions/erasmus-mc/), [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://nuclide.cc/institutions/inselspital-bern/), [IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)](https://nuclide.cc/institutions/irst-meldola/), [Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center](https://nuclide.cc/institutions/johns-hopkins/), [Oslo University Hospital, The Norwegian Radium Hospital](https://nuclide.cc/institutions/oslo-radium-hospital/), [Peter MacCallum Cancer Centre](https://nuclide.cc/institutions/peter-mac/), [QST Hospital (National Institutes for Quantum Science and Technology)](https://nuclide.cc/institutions/qst-hospital/), [Radboudumc Centre for Oncology](https://nuclide.cc/institutions/radboudumc/), [The Royal Marsden](https://nuclide.cc/institutions/royal-marsden/), [TUM Klinikum rechts der Isar / CCC München](https://nuclide.cc/institutions/tum-munich/), [UCLA Jonsson Comprehensive Cancer Center](https://nuclide.cc/institutions/ucla-jonsson/), [University Hospital Düsseldorf / CIO Düsseldorf](https://nuclide.cc/institutions/uk-duesseldorf/), [Uppsala University Hospital / Uppsala University](https://nuclide.cc/institutions/uppsala-akademiska/), [West German Cancer Center (WTZ), University Hospital Essen](https://nuclide.cc/institutions/essen-wtz/)
- pathways: [Lineage plasticity & neuroendocrine transformation](https://nuclide.cc/pathways/lineage-plasticity-neuroendocrine/), [Prostate cancer (KEGG map)](https://nuclide.cc/pathways/prostate-cancer-signalling/)
- terms: [Androgen receptor pathway inhibitor (ARPI)](https://nuclide.cc/terms/arpi/), [Biochemical recurrence (BCR)](https://nuclide.cc/terms/biochemical-recurrence/), [Bone metastases and skeletal-related events](https://nuclide.cc/terms/bone-metastases/), [Crossover in trials](https://nuclide.cc/terms/crossover/), [mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)](https://nuclide.cc/terms/mcrpc-mhspc/), [Oligometastatic disease](https://nuclide.cc/terms/oligometastatic/), [PSA50 / PSA90 response](https://nuclide.cc/terms/psa50/), [Radical prostatectomy](https://nuclide.cc/terms/prostatectomy/), [Theranostics](https://nuclide.cc/terms/theranostics/)
- trials: [[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer](https://nuclide.cc/trials/nct05936658/), [177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors](https://nuclide.cc/trials/nct07189871/), [64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)](https://nuclide.cc/trials/nct04868604/), [A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer](https://nuclide.cc/trials/nct07258407/), [A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy](https://nuclide.cc/trials/nct05547061/), [A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC](https://nuclide.cc/trials/nct06383052/), [A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA](https://nuclide.cc/trials/nct07226986/), [A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC](https://nuclide.cc/trials/nct05849298/), [A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer](https://nuclide.cc/trials/nct07311694/), [A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS](https://nuclide.cc/trials/nct06906471/), [A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer](https://nuclide.cc/trials/nct05658003/), [A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer](https://nuclide.cc/trials/nct04557059/), [A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer](https://nuclide.cc/trials/nct06990880/), [A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)](https://nuclide.cc/trials/nct07047118/), [A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)](https://nuclide.cc/trials/mcrpc/), [A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC](https://nuclide.cc/trials/nct07259213/), [A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC](https://nuclide.cc/trials/nct07567521/), [A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta](https://nuclide.cc/trials/nct03972657/), [AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)](https://nuclide.cc/trials/alphabreak/), [ALSYMPCA](https://nuclide.cc/trials/alsympca/), [An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.](https://nuclide.cc/trials/nct05939414/), [An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC](https://nuclide.cc/trials/nct06894511/), [Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection](https://nuclide.cc/trials/nct05413850/), [AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)](https://nuclide.cc/trials/nct07611110/), [Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer](https://nuclide.cc/trials/nct03444844/), [CHAARTED (E3805)](https://nuclide.cc/trials/chaarted/), [Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer](https://nuclide.cc/trials/nct06235151/), [Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer](https://nuclide.cc/trials/nct06122584/), [ECLIPSE](https://nuclide.cc/trials/eclipse-psma/), [EMBARK](https://nuclide.cc/trials/embark/), [Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis](https://nuclide.cc/trials/nct05004285/), [FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)](https://nuclide.cc/trials/nct06909825/), [Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.](https://nuclide.cc/trials/nct07615101/), [ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC](https://nuclide.cc/trials/nct05682443/), [Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy](https://nuclide.cc/trials/nct06780670/), [Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer](https://nuclide.cc/trials/nct06139575/), [Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer](https://nuclide.cc/trials/nct07590934/), [POP-RT](https://nuclide.cc/trials/pop-rt/), [proPSMA](https://nuclide.cc/trials/propsma/), [PROSPER](https://nuclide.cc/trials/prosper/), [PSMA PET Combined With MRI for the Detection of PCa](https://nuclide.cc/trials/nct07052214/), [PSMA-PET to Guide Prostatectomy](https://nuclide.cc/trials/nct05381103/), [PSMAddition](https://nuclide.cc/trials/psmaddition/), [PSMAfore](https://nuclide.cc/trials/psmafore/), [Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer](https://nuclide.cc/trials/nct06474806/), [SPLASH](https://nuclide.cc/trials/splash/), [STAMPEDE](https://nuclide.cc/trials/stampede/), [Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC](https://nuclide.cc/trials/nct06855277/), [Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)](https://nuclide.cc/trials/nct06549465/), [Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer](https://nuclide.cc/trials/nct06754085/), [Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function](https://nuclide.cc/trials/nct06004661/), [Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).](https://nuclide.cc/trials/nct05219500/), [The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)](https://nuclide.cc/trials/nct06520345/), [TheraP (ANZUP 1603)](https://nuclide.cc/trials/therap/), [This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.](https://nuclide.cc/trials/nct07649122/), [VISION](https://nuclide.cc/trials/vision/)
- ideas: [Alpha-emitting PSMA therapy at first metastatic diagnosis](https://nuclide.cc/ideas/idea-alpha-first-mhspc/), [PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer](https://nuclide.cc/ideas/idea-psma-pet-guided-mdt/), [Qualify PSMA PET tumour volume as a validated imaging biomarker](https://nuclide.cc/ideas/idea-tr2-psma-volume-qualification/), [Total-body PET for personalised radioligand dosing](https://nuclide.cc/ideas/idea-total-body-pet-dosimetry/)
- indications: [Biochemical recurrence of prostate cancer](https://nuclide.cc/indications/prostate-bcr/), [Localised prostate cancer, high and very high risk](https://nuclide.cc/indications/prostate-high-risk/), [Metastatic castration-resistant prostate cancer](https://nuclide.cc/indications/prostate-mcrpc/), [Metastatic hormone-sensitive prostate cancer](https://nuclide.cc/indications/prostate-mhspc/), [Neuroendocrine and small-cell prostate cancer](https://nuclide.cc/indications/prostate-nepc/), [Non-metastatic castration-resistant prostate cancer](https://nuclide.cc/indications/prostate-nmcrpc/)
- people: [A. Oliver Sartor](https://nuclide.cc/people/oliver-sartor/), [Chris C. Parker](https://nuclide.cc/people/chris-parker/), [Clemens Kratochwil](https://nuclide.cc/people/clemens-kratochwil/), [Declan G. Murphy](https://nuclide.cc/people/declan-murphy/), [Jeremie Calais](https://nuclide.cc/people/jeremie-calais/), [Johannes Czernin](https://nuclide.cc/people/johannes-czernin/), [Karim Fizazi](https://nuclide.cc/people/karim-fizazi/), [Ken Herrmann](https://nuclide.cc/people/ken-herrmann/), [Louise Emmett](https://nuclide.cc/people/louise-emmett/), [Michael Hofman](https://nuclide.cc/people/hofman-michael/), [Michael J. Morris](https://nuclide.cc/people/michael-morris/), [Paola Anna Erba](https://nuclide.cc/people/paola-anna-erba/), [Peter Bartenstein](https://nuclide.cc/people/peter-bartenstein/), [Rahul Aggarwal](https://nuclide.cc/people/rahul-aggarwal/), [Richard P. Baum](https://nuclide.cc/people/richard-baum/), [Shahneen Sandhu](https://nuclide.cc/people/sandhu-shahneen/), [Silke Gillessen](https://nuclide.cc/people/silke-gillessen/), [Thomas A. Hope](https://nuclide.cc/people/thomas-hope/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://nuclide.cc/bottlenecks/b-manufacturing-cell-therapy/)
- key papers: [Appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging](https://nuclide.cc/key-papers/paper-jadvar-snmmi-psma-auc-jnm-2022/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://nuclide.cc/key-papers/paper-vision-nejm-2021/)
- journals: [European Urology](https://nuclide.cc/journals/european-urology/)
- fronts: [Molecular imaging](https://nuclide.cc/fronts/f-molecular-imaging/)

---
JSON: https://nuclide.cc/api/v1/entities/prostate.json